|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zong L, Abe M, Seto Y and Ji J: The
challenge of screening for early gastric cancer in China. Lancet.
388:26062016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cervantes A, Roda D, Tarazona N, Roselló S
and Pérez-Fidalgo JA: Current questions for the treatment of
advanced gastric cancer. Cancer Treat Rev. 39:60–67. 2013.
View Article : Google Scholar
|
|
5
|
Glockzin G and Piso P: Current status and
future directions in gastric cancer with peritoneal dissemination.
Surg Oncol Clin N Am. 21:625–633. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu JJ, Liu JY, Chen J, Wu YX, Yan P, Ji
CD, Wang YX, Xiang DF, Zhang X, Zhang P, et al: Scinderin promotes
the invasion and metastasis of gastric cancer cells and predicts
the outcome of patients. Cancer Lett. 376:110–117. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Morén A, Olofsson A, Stenman G, Sahlin P,
Kanzaki T, Claesson-Welsh L, ten Dijke P, Miyazono K and Heldin CH:
Identification and characterization of LTBP-2, a novel latent
transforming growth factor-beta-binding protein. J Biol Chem.
269:32469–32478. 1994.PubMed/NCBI
|
|
8
|
Jensen SA, Robertson IB and Handford PA:
Dissecting the fibrillin microfibril: Structural insights into
organization and function. Structure. 20:215–225. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Miyazono K, Olofsson A, Colosetti P and
Heldin CH: A role of the latent TGF-beta 1-binding protein in the
assembly and secretion of TGF-beta 1. EMBO J. 10:1091–1101.
1991.PubMed/NCBI
|
|
10
|
Anderson SB, Goldberg AL and Whitman M:
Identification of a novel pool of extracellular pro-myostatin in
skeletal muscle. J Biol Chem. 283:7027–7035. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jelodari-Mamaghani S, Haji-Seyed-Javadi R,
Suri F, Nilforushan N, Yazdani S, Kamyab K and Elahi E:
Contribution of the latent transforming growth factor-β binding
protein 2 gene to etiology of primary open angle glaucoma and
pseudoexfoliation syndrome. Mol Vis. 19:333–347. 2013.
|
|
12
|
Kumar A, Duvvari MR, Prabhakaran VC,
Shetty JS, Murthy GJ and Blanton SH: A homozygous mutation in LTBP2
causes isolated microspherophakia. Hum Genet. 128:365–371. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Haji-Seyed-Javadi R, Jelodari-Mamaghani S,
Paylakhi SH, Yazdani S, Nilforushan N, Fan JB, Klotzle B, Mahmoudi
MJ, Ebrahimian MJ, Chelich N, et al: LTBP2 mutations cause
Weill-Marchesani and Weill-Marchesani-like syndrome and affect
disruptions in the extracellular matrix. Hum Mutat. 33:1182–1187.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Breidthardt T, Vanpoucke G, Potocki M,
Mosimann T, Ziller R, Thomas G, Laroy W, Moerman P, Socrates T,
Drexler B, et al: The novel marker LTBP2 predicts all-cause and
pulmonary death in patients with acute dyspnoea. Clin Sci (Lond).
123:557–566. 2012. View Article : Google Scholar
|
|
15
|
Han L, Tang MM, Xu X, Jiang B, Huang J,
Feng X and Qiang J: LTBP2 is a prognostic marker in head and neck
squamous cell carcinoma. Oncotarget. 7:45052–45059. 2016.PubMed/NCBI
|
|
16
|
Yoshihara K, Tajima A, Komata D, Yamamoto
T, Kodama S, Fujiwara H, Suzuki M, Onishi Y, Hatae M, Sueyoshi K,
et al: Gene expression profiling of advanced-stage serous ovarian
cancers distinguishes novel subclasses and implicates ZEB2 in tumor
progression and prognosis. Cancer Sci. 100:1421–1428. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ren Y, Lu H, Zhao D, Ou Y, Yu K, Gu J,
Wang L, Jiang S, Chen M, Wang J, et al: LTPB2 acts as a prognostic
factor and promotes progression of cervical adenocarcinoma. Am J
Transl Res. 7:1095–1105. 2015.PubMed/NCBI
|
|
18
|
Wan F, Peng L, Zhu C, Zhang X, Chen F and
Liu T: Knockdown of latent transforming growth factor-β
(TGF-β)-binding protein 2 (LTBP2) inhibits invasion and
tumorigenesis in thyroid carcinoma cells. Oncol Res. 25:503–510.
2017. View Article : Google Scholar
|
|
19
|
da Costa AN, Plymoth A, Santos-Silva D,
Ortiz-Cuaran S, Camey S, Guilloreau P, Sangrajrang S, Khuhaprema T,
Mendy M, Lesi OA, et al: Osteopontin and latent-TGF β
binding-protein 2 as potential diagnostic markers for HBV-related
hepatocellular carcinoma. Int J Cancer. 172–181. 2015. View Article : Google Scholar
|
|
20
|
Chan SH, Yee Ko JM, Chan KW, Chan YP, Tao
Q, Hyytiainen M, Keski-Oja J, Law S, Srivastava G, Tang J, et al:
The ECM protein LTBP-2 is a suppressor of esophageal squamous cell
carcinoma tumor formation but higher tumor expression associates
with poor patient outcome. Int J Cancer. 129:565–573. 2011.
View Article : Google Scholar
|
|
21
|
Kan R, Shuen WH, Lung HL, Cheung AK, Dai
W, Kwong DL, Ng WT, Lee AW, Yau CC, Ngan RK, et al: NF-κB p65
subunit is modulated by latent transforming growth factor-β binding
protein 2 (LTBP2) in nasopharyngeal carcinoma HONE1 and HK1 cells.
PLoS One. 10:e01272392015. View Article : Google Scholar
|
|
22
|
Washington K: 7th edition of the AJCC
cancer staging manual: Stomach. Ann Surg Oncol. 17:3077–3079. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Camp RL, Dolled-Filhart M and Rimm DL:
X-tile: A new bio-informatics tool for biomarker assessment and
outcome-based cut-point optimization. Clin Cancer Res.
10:7252–7259. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gentleman RC, Carey VJ, Bates DM, Bolstad
B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al:
Bioconductor: Open software development for computational biology
and bioinformatics. Genome Biol. 5:R802004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Förster S, Gretschel S, Jöns T, Yashiro M
and Kemmner W: THBS4, a novel stromal molecule of diffuse-type
gastric adenocarcinomas, identified by transcriptome-wide
expression profiling. Mod Pathol. 24:1390–1403. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A,
Yamada Y, Arao T, Nishio K, Michalowski A and Green JE: Three-gene
predictor of clinical outcome for gastric cancer patients treated
with chemotherapy. Pharmacogenomics J. 12:119–127. 2012. View Article : Google Scholar :
|
|
28
|
Szász AM, Lánczky A, Nagy Á, Förster S,
Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A and Győrffy B:
Cross-validation of survival associated biomarkers in gastric
cancer using transcriptomic data of 1,065 patients. Oncotarget.
7:49322–49333. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
30
|
Wang S, Cheng Y, Du W, Lu L, Zhou L, Wang
H, Kang W, Li X, Tao Q, Sung JJ, et al: Zinc-finger protein 545 is
a novel tumour suppressor that acts by inhibiting ribosomal RNA
transcription in gastric cancer. Gut. 62:833–841. 2013. View Article : Google Scholar
|
|
31
|
Yie SM, Ye SR, Ma XL, Xie K, Zhang JB, Cao
M, He X, Hu ZB, Yang CL, Zhang J, et al: A protein fragment derived
from DNA-topoisomerase I as a novel tumour-associated antigen for
the detection of early stage carcinoma. Br J Cancer. 115:1555–1564.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Prieto-García E, Díaz-García CV,
García-Ruiz I and Agulló-Ortuño MT: Epithelial-to-mesenchymal
transition in tumor progression. Med Oncol. 34:1222017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sun J, Sun B, Zhu D, Zhao X, Zhang Y, Dong
X, Che N, Li J, Liu F, Zhao N, et al: HMGA2 regulates CD44
expression to promote gastric cancer cell motility and sphere
formation. Am J Cancer Res. 7:260–274. 2017.PubMed/NCBI
|
|
34
|
Massagué J: TGFβ signalling in context.
Nat Rev Mol Cell Biol. 13:616–630. 2012. View Article : Google Scholar
|
|
35
|
Heldin CH, Vanlandewijck M and Moustakas
A: Regulation of EMT by TGFβ in cancer. FEBS Lett. 586:1959–1970.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ikushima H and Miyazono K: TGF-β signal
transduction spreading to a wider field: A broad variety of
mechanisms for context-dependent effects of TGF-β. Cell Tissue Res.
347:37–49. 2012. View Article : Google Scholar
|
|
37
|
Massagué J: TGFbeta in cancer. Cell.
134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Brunner AM, Marquardt H, Malacko AR,
Lioubin MN and Purchio AF: Site-directed mutagenesis of cysteine
residues in the pro region of the transforming growth factor beta 1
precursor. Expression and characterization of mutant proteins. J
Biol Chem. 264:13660–13664. 1989.PubMed/NCBI
|
|
39
|
Ono RN, Sengle G, Charbonneau NL, Carlberg
V, Bächinger HP, Sasaki T, Lee-Arteaga S, Zilberberg L, Rifkin DB,
Ramirez F, et al: Latent transforming growth factor beta-binding
proteins and fibulins compete for fibrillin-1 and exhibit exquisite
specificities in binding sites. J Biol Chem. 284:16872–16881. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Saharinen J and Keski-Oja J: Specific
sequence motif of 8-Cys repeats of TGF-beta binding proteins,
LTBPs, creates a hydrophobic interaction surface for binding of
small latent TGF-beta. Mol Biol Cell. 11:2691–2704. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hirani R, Hanssen E and Gibson MA: LTBP-2
specifically interacts with the amino-terminal region of
fibrillin-1 and competes with LTBP-1 for binding to this
microfibrillar protein. Matrix Biol. 26:213–223. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Turtoi A, Blomme A, Debois D, Somja J,
Delvaux D, Patsos G, Di Valentin E, Peulen O, Mutijima EN, De Pauw
E, et al: Organized proteomic heterogeneity in colorectal cancer
liver metastases and implications for therapies. Hepatology.
59:924–934. 2014. View Article : Google Scholar
|
|
43
|
Turtoi A, Musmeci D, Wang Y, Dumont B,
Somja J, Bevilacqua G, De Pauw E, Delvenne P and Castronovo V:
Identification of novel accessible proteins bearing diagnostic and
therapeutic potential in human pancreatic ductal adenocarcinoma. J
Proteome Res. 10:4302–4313. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen H, Ko JM, Wong VC, Hyytiainen M,
Keski-Oja J, Chua D, Nicholls JM, Cheung FM, Lee AW, Kwong DL, et
al: LTBP-2 confers pleiotropic suppression and promotes dormancy in
a growth factor permissive microenvironment in nasopharyngeal
carcinoma. Cancer Lett. 325:89–98. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nieto MA, Huang RY, Jackson RA and Thiery
JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kitamura K, Kasuya K, Tsuchida A, Mimuro
A, Inoue K, Aoki T, Aoki T and Koyanagi Y: Immunohistochemical
analysis of transforming growth factor beta in gallbladder cancer.
Oncol Rep. 10:327–332. 2003.PubMed/NCBI
|
|
47
|
Fukai Y, Fukuchi M, Masuda N, Osawa H,
Kato H, Nakajima T and Kuwano H: Reduced expression of transforming
growth factor-beta receptors is an unfavorable prognostic factor in
human esophageal squamous cell carcinoma. Int J Cancer.
104:161–166. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sato Y, Harada K, Itatsu K, Ikeda H,
Kakuda Y, Shimomura S, Shan Ren X, Yoneda N, Sasaki M and Nakanuma
Y: Epithelial-mesenchymal transition induced by transforming growth
factor-{beta}1/Snail activation aggravates invasive growth of
cholangiocarcinoma. Am J Pathol. 177:141–152. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ma GF, Miao Q, Zeng XQ, Luo TC, Ma LL, Liu
YM, Lian JJ, Gao H and Chen SY: Transforming growth factor-β1 and
-β2 in gastric precancer and cancer and roles in tumor-cell
interactions with peripheral blood mononuclear cells in vitro. PLoS
One. 8:e542492013. View Article : Google Scholar
|
|
50
|
Voon DC, Wang H, Koo JK, Chai JH, Hor YT,
Tan TZ, Chu YS, Mori S and Ito Y: EMT-induced stemness and
tumorigenicity are fueled by the EGFR/Ras pathway. PLoS One.
8:e704272013. View Article : Google Scholar : PubMed/NCBI
|
